These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
35. Meta-analysis of CMVIG studies for the prevention and treatment of CMV infection in transplant patients. Wittes JT; Kelly A; Plante KM Transplant Proc; 1996 Dec; 28(6 Suppl 2):17-24. PubMed ID: 9037273 [No Abstract] [Full Text] [Related]
36. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection. Reischig T; Jindra P; Svecová M; Kormunda S; Opatrný K; Treska V J Clin Virol; 2006 Jun; 36(2):146-51. PubMed ID: 16531113 [TBL] [Abstract][Full Text] [Related]
37. Cytomegalovirus disease in renal transplant recipients: a single-center experience. Basri N; Abdullah KA; Shaheen FA Exp Clin Transplant; 2007 Jun; 5(1):601-3. PubMed ID: 17617050 [TBL] [Abstract][Full Text] [Related]
38. A randomized double-blind study of the effect of prophylactic immune globulin on the incidence and severity of CMV infection in the liver transplant recipient. Cofer JB; Morris CA; Sutker WL; Husberg BS; Goldstein RM; Gonwa TA; Klintmalm GB Transplant Proc; 1991 Feb; 23(1 Pt 2):1525-7. PubMed ID: 1846477 [No Abstract] [Full Text] [Related]
39. Prevention of cytomegalovirus disease in transplant recipients. Pidgeon GB; Bailey RR N Z Med J; 1993 Nov; 106(967):468-9. PubMed ID: 8233192 [No Abstract] [Full Text] [Related]
40. The usefulness of hyperimmune globulin for treatment of overt cytomegalovirus infection in allograft recipients. Rancewicz Z; Halama G; Smogorzewski M; Durlik M; Rowinska D; Lao M; Juskowa J; Wyzgal J Transplant Proc; 1990 Aug; 22(4):1818-9. PubMed ID: 2167538 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]